We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Investigational Drug Fails As Standalone Mesothelioma Treatment, AstraZeneca Says

(February 29, 2016, 10:38 AM EST) -- LONDON — The investigational drug Tremelimumab does not improve overall survival rates of mesothelioma patients when used alone, AstraZeneca announced Feb. 29.

In its release, AstraZeneca said Tremelimumab remains a key...
To view the full article, register now.